3D-printed heart valves could reduce leakage in aortic valve replacements

3D printing has made a name for itself in the production of blood vessels, cartilage and a number of medical devices. Now, a team from the Georgia Institute of Technology and Piedmont Heart Institute are looking to test 3D-printed transcatheter aortic valve replacements (TAVR) for leakage before implantation.

The team produced models comparable to biological tissues via 3D printing. They then tried to develop a simulation platform for TAVR procedures that would allow for cardiologists to predict paravalvular leakage, which affects 26 to 67 percent of TAVR patients.

"Paravalvular leakage is an extremely important indicator in how well the patient will do long term with their new valve," said Zhen Qian, chief of cardiovascular imaging research at Georgia-based Piedmont Heart Institute. "The idea was, now that we can make a patient-specific model with this tissue-mimicking 3D printing technology, we can test how the prosthetic valves interact with the 3D printed models to learn whether we can predict leakage."

Read more here:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup